Retatrutide + CJC-1295 + Ipamorelin
No clinical trial has studied this three-compound combination. Neither CJC-1295 nor ipamorelin is approved for human use. Retatrutide is not FDA approved. All rationale is anecdotal.
This page reviews what is known about combining retatrutide with CJC-1295 and ipamorelin: the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
CJC-1295 and ipamorelin are frequently combined in peptide communities for synergistic GH release — CJC-1295 extends the GH pulse while ipamorelin amplifies it. Adding retatrutide to this stack is discussed for aggressive fat loss with lean mass support. The three-compound combination is discussed anecdotally with no clinical evidence.
Human Evidence
No published clinical trial has studied retatrutide combined with CJC-1295 and ipamorelin. Neither CJC-1295 nor ipamorelin has an approved human indication. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for this combination.
Theoretical Rationale
The theoretical rationale combines two mechanisms: retatrutide's appetite suppression and metabolic effects for fat loss, and the CJC-1295/ipamorelin combination's GH secretagogue effects for lean mass support. CJC-1295 (with DAC) extends GH pulse duration; ipamorelin amplifies GH release with purportedly selective action. Whether this GH stimulation would meaningfully offset lean mass loss during retatrutide treatment is unknown.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- CJC-1295 + Ipamorelin: Water retention, joint pain, potential effects on insulin sensitivity and cortisol; long-term safety unknown
- Combined (three compounds): Unknown interaction risks; no safety data for this combination exists; neither CJC-1295 nor ipamorelin is approved for human use
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss. The CJC-1295/ipamorelin combination is discussed for body recomposition in peptide communities but lacks robust human clinical evidence. No body composition data exists for the three-compound combination.
What People Are Discussing Online
Reddit communities (r/Peptides, r/PeptideScience) discuss this three-compound stack as a body recomposition protocol. Common claims include superior lean mass preservation and accelerated fat loss versus retatrutide alone. These claims are anecdotal. The combination of three unapproved or investigational compounds compounds unknown safety risks.
Regulatory and Legal Context
Neither CJC-1295 nor ipamorelin is approved for human use. Both are sold as research chemicals. Retatrutide is not FDA approved. Using three unapproved or investigational compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied this three-compound combination. Neither CJC-1295 nor ipamorelin is approved for human use. No safety or efficacy data exists for this combination.
CJC-1295 and ipamorelin are frequently combined for synergistic GH release. Adding retatrutide is discussed for aggressive fat loss with lean mass support. All rationale is anecdotal.
The risks are unknown because the combination has not been studied. Using multiple unapproved compounds simultaneously compounds unknown safety risks.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW